clinical trial · NCT07830758
Resmetirom in Patients With MASH and HFpEF
MASH - Metabolic Dysfunction-Associated SteatohepatitisHeart Failure With Preserved Ejection Fraction (HFPEF)ResmetiromPlacebo
brief summary
This Phase 1b multicenter randomized double-blind placebo-controlled study evaluates the safety, tolerability and hepatic pharmacodynamic effects of resmetirom in adults with metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction (HFpEF). Participants are randomized 2:1 to resmetirom or placebo for 24 weeks.
started
Sep 1, 2026
primary completion
Nov 1, 2027
completion
Dec 1, 2027
last updated
Oct 16, 2026
official title
A Phase 1b, Multi-Center, Double-Blind (Sponsor Unblinded), Randomized, Placebo-Controlled Study of the Safety, Tolerability, and Hepatic Pharmacodynamics of Resmetirom in Patients With Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Heart Failure With Preserved Ejection Fraction (HFpEF)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol